Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 9;12(5):e057384.
doi: 10.1136/bmjopen-2021-057384.

Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings

Christopher P Millward  1   2 , Terri S Armstrong  3 , Heather Barrington  4 , Sabrina Bell  5 , Andrew R Brodbelt  6   2 , Helen Bulbeck  7 , Anna Crofton  2 , Linda Dirven  8   9 , Theo Georgious  5 , Paul L Grundy  10 , Abdurrahman I Islim  6   2 , Mohsen Javadpour  11 , Sumirat M Keshwara  6   2 , Shelli D Koszdin  12 , Anthony G Marson  6   13 , Michael W McDermott  14 , Torstein R Meling  15 , Kathy Oliver  16 , Puneet Plaha  17 , Matthias Preusser  18 , Thomas Santarius  19 , Nisaharan Srikandarajah  6   2 , Martin J B Taphoorn  8   9 , Carole Turner  19 , Colin Watts  20 , Michael Weller  21 , Paula R Williamson  4 , Gelareh Zadeh  22 , Amir H Zamanipoor Najafabadi  23 , Michael D Jenkinson  6   2 ; EORTC BTG, ICOM, EANO, SNO, RANO-PRO, BNOS, SBNS, BIMS, TBTC, International Brain Tumour Alliance, Brainstrust, and Brain Tumour Foundation of Canada
Collaborators, Affiliations

Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings

Christopher P Millward et al. BMJ Open. .

Abstract

Introduction: Meningioma is the most common primary intracranial tumour in adults. The majority are non-malignant, but a proportion behave more aggressively. Incidental/minimally symptomatic meningioma are often managed by serial imaging. Symptomatic meningioma, those that threaten neurovascular structures, or demonstrate radiological growth, are usually resected as first-line management strategy. For patients in poor clinical condition, or with inoperable, residual or recurrent disease, radiotherapy is often used as primary or adjuvant treatment. Effective pharmacotherapy treatments do not currently exist. There is heterogeneity in the outcomes measured and reported in meningioma clinical studies. Two 'Core Outcome Sets' (COS) will be developed: (COSMIC: Intervention) for use in meningioma clinical effectiveness trials and (COSMIC: Observation) for use in clinical studies of incidental/untreated meningioma.

Methods and analysis: Two systematic literature reviews and trial registry searches will identify outcomes measured and reported in published and ongoing (1) meningioma clinical effectiveness trials, and (2) clinical studies of incidental/untreated meningioma. Outcomes include those that are clinician reported, patient reported, caregiver reported and based on objective tests (eg, neurocognitive tests), as well as measures of progression and survival. Outcomes will be deduplicated and categorised to generate two long lists. The two long lists will be prioritised through two, two-round, international, modified eDelphi surveys including patients with meningioma, healthcare professionals, researchers and those in caring/supporting roles. The two final COS will be ratified through two 1-day online consensus meetings, with representation from all stakeholder groups.

Ethics and dissemination: Institutional review board (University of Liverpool) approval was obtained for the conduct of this study. Participant eConsent will be obtained prior to participation in the eDelphi surveys and consensus meetings. The two systematic literature reviews and two final COS will be published and freely available.

Trial registration number: COMET study ID 1508.

Keywords: clinical trial; core outcome set; meningioma.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MDJ received a grant from the National Institute for Health Research Health Technology Assessment programme for the Radiation versus Observation for Atypical Meningioma (ROAM) trial (NIHR ID: 12/173/14). MDJ received a grant from the National Institute for Health Research Health Technology Assessment programme for Surgeons Trial Of Prophylaxis for Epilepsy in seizure-naïve patients with Meningioma (STOP'EM) (NIHR ID: NIHR129748). TS founded and leads the Anaplastic Meningioma International Consortium (AMICo). TS and MDJ co-founded the British-Irish Meningioma Society (BIMS). MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra. The following for-profit companies have supported clinical trials and contracted research conducted by MP with payments made to his institution: Boehringer Ingelheim, Bristol Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GlaxoSmithKline, AbbVie. MW has received research grants from Apogenix, Merck Sharp & Dohme, Merck (EMD) and Quercis, and honoraria for lectures or advisory board participation or consulting from Adastra, Bristol Myers Squibb, Medac, Merck Sharp & Dohme, Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen and yMabs.

Figures

Figure 1
Figure 1
A flow chart summarising the five stages of The COSMIC Project. COS, core outcome set.
See this image and copyright information in PMC

References

    1. Ostrom QT, Patil N, Cioffi G, et al. . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 2020;22:iv1–96. 10.1093/neuonc/noaa200 - DOI - PMC - PubMed
    1. Louis DN, Perry A, Wesseling P. The 2021 who classification of tumors of the central nervous system: a summary. Neuro Oncol 2021. 10.1093/neuonc/noab106 - DOI - PMC - PubMed
    1. Rogers L, Barani I, Chamberlain M, et al. . Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015;122:4–23. 10.3171/2014.7.JNS131644 - DOI - PMC - PubMed
    1. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. . EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 2021;23:1821–34. 10.1093/neuonc/noab150 - DOI - PMC - PubMed
    1. Goldbrunner R, Minniti G, Preusser M, et al. . EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 2016;17:e383:91–391. 10.1016/S1470-2045(16)30321-7 - DOI - PubMed

Publication types